TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34817837

Group type: EXPERIMENTAL
Intervention: 2020 surgical volume
Number of subjects: 1423

Group type: EXPERIMENTAL
Intervention: 2020 treatment of benign/precursors diseases
Number of subjects: 1423

Group type: EXPERIMENTAL
Intervention: 2020 treatment of neuroendocrine tumors
Number of subjects: 1423

Group type: EXPERIMENTAL
Intervention: 2020 laparoscopic procedures
Number of subjects: 1423

Group type: EXPERIMENTAL
Intervention: 2020 robot-assisted procedures
Number of subjects: 1423

Group type: COMPARATOR
Intervention: Post-operative intensive care unit accesses
Number of subjects: 1423

Group type: COMPARATOR
Intervention: Post-operative mortality
Number of subjects: 1423
Study: 34817851

Group type: COMPARATOR
Intervention: n-3 polyunsaturated fatty acids (n-3PUFAs)
Number of subjects: 1924
Study: 34818097

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34818379

Group type: EXPERIMENTAL
Intervention: Voriconazole treatment
Number of subjects: 70
Study: 34818478

Group type: EXPERIMENTAL
Intervention: Belzutifan (MK-6482) 120 mg daily
Number of subjects: 0
Study: 34818581

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (allo-SCT) during time period A (2000 to 2005)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (allo-SCT) during time period B (2006 to 2011)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (allo-SCT) during time period C (2012 to 2017)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) score correlation with 2-year NRM (2000 to 2011)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Overall findings from the study
Number of subjects: 1996
Study: 34818921

Group type: EXPERIMENTAL
Intervention: Preoperative hypnosis
Number of subjects: 1049
Study: 34818965

Group type: EXPERIMENTAL
Intervention: Elotuzumab in combination with pomalidomide, carfilzomib, and low-dose dexamethasone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Elotuzumab in combination with pomalidomide, carfilzomide, and low-dose dexamethasone
Number of subjects: 13
Study: 34819019

Group type: EXPERIMENTAL
Intervention: SARS-CoV infection
Number of subjects: 58
Study: 34819039

Group type: EXPERIMENTAL
Intervention: Entinostat monotherapy (3 mg/qw, 5 mg/qw, or 10 mg/q2w)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Entinostat combined with exemestane (5 mg/qw + 25 mg/qd)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Entinostat monotherapy and combined entinostat/exemestane
Number of subjects: 12
Study: 34819116

Group type: EXPERIMENTAL
Intervention: Osteopathic treatment in addition to treatment as usual (TAU) - 5 sessions of 30 minutes each, using soft specific palpatory techniques on the diaphragm, digestive system, and cervical region.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only.
Number of subjects: 72
Study: 34819117

Group type: EXPERIMENTAL
Intervention: WeChat mini-program-based lactation consultant intervention
Number of subjects: 12
Study: 34819138

Group type: EXPERIMENTAL
Intervention: Injection of autologous adipose tissue (AT) around the anal fistula tract
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cultured AT-MSCs in the responder group
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cultured AT-MSCs in the non-responder group
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: AT-MSCs of responders
Number of subjects: 27
Study: 34819160

Group type: EXPERIMENTAL
Intervention: Seropositivity to Helicobacter pylori
Number of subjects: 12471

Group type: EXPERIMENTAL
Intervention: Seropositivity to hepatitis A virus (HAV)
Number of subjects: 12471

Group type: EXPERIMENTAL
Intervention: Overall asthma prevalence
Number of subjects: 12471

Group type: EXPERIMENTAL
Intervention: Weighted seroprevalence of H. pylori
Number of subjects: 12471

Group type: EXPERIMENTAL
Intervention: Weighted seroprevalence of HAV
Number of subjects: 12471

Group type: EXPERIMENTAL
Intervention: Analysis stratified by Hispanic/Latino background
Number of subjects: 12471

Group type: EXPERIMENTAL
Intervention: Analysis restricted to individuals with spirometry-defined COPD
Number of subjects: 12471

Group type: EXPERIMENTAL
Intervention: Interactions by smoking and nativity
Number of subjects: 12471
Study: 34819278

Group type: EXPERIMENTAL
Intervention: CYPHP (Children and Young People's Health Partnership) model of care
Number of subjects: 2138

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 2138

Group type: EXPERIMENTAL
Intervention: CYPHP model of care
Number of subjects: 2138
Study: 34819277

Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Education Program (DiPEP) package including intensive intervention classes, diabetes prevention brochure, exercise calendar, and food record booklet
Number of subjects: 448

Group type: COMPARATOR
Intervention: Diabetes prevention brochure
Number of subjects: 448
Study: 34819284

Group type: EXPERIMENTAL
Intervention: Prismatic adaptation (performing pointing tasks while wearing glasses shifting optical axis of 10 degrees towards the right side)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (performing the same procedure while wearing neutral glasses without optical deviation)
Number of subjects: 28
Study: 34819613

Group type: EXPERIMENTAL
Intervention: Increased PBR (Perfused Boundary Region) indicates reduced glycocalyx thickness.
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Indexes of microvascular perfusion including red blood cells filling (RBCF) and functional microvascular density.
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Markers of myocardial deformation by speckle-tracking imaging, namely global longitudinal strain (GLS) and percentage changes between peak twisting and untwisting at mitral valve opening (%dpTw-Utw).
Number of subjects: 297
Study: 34819793

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid (DHA) supplementation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no DHA supplementation)
Number of subjects: 67
Study: 34819906

Group type: EXPERIMENTAL
Intervention: Extracellular vesicles
Number of subjects: 0
Study: 34819911

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34820133

Group type: EXPERIMENTAL
Intervention: Cisplatin therapy
Number of subjects: 600
Study: 34820927

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34821990

Group type: EXPERIMENTAL
Intervention: Blue-yellow pattern visually evoked potentials (BY-VEP) recorded using a video projector (DLP technology) with a blue checkerboard pattern (460 nm) for 200 ms superimposed on a bright yellow background (574 nm).
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Blue-yellow pattern visually evoked potentials (BY-VEP) recorded using a video projector (DLP technology).
Number of subjects: 126
Study: 34822023

Group type: EXPERIMENTAL
Intervention: Plasma neutrophil gelatinase associated lipocalin (NGAL) levels measured at 6 and 24 hours post-surgery.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Perioperative measurements including plasma creatinine, blood urinary nitrogen, plasma lactate, urine output, and NGAL.
Number of subjects: 60
Study: 34822048

Group type: EXPERIMENTAL
Intervention: Mothers
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Fathers
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Low adaptive skills and high aberrant behaviors in children
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Child's internalized disorders
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Child's externalized disorders
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Parental factors (family association, training in ASD, disruption in professional activity)
Number of subjects: 260
Study: 34822118

Group type: EXPERIMENTAL
Intervention: Peace of Mind Program intervention
Number of subjects: 4402

Group type: EXPERIMENTAL
Intervention: Peace of Mind Program intervention (completed)
Number of subjects: 4402

Group type: COMPARATOR
Intervention: Baseline period (usual care)
Number of subjects: 4402

Group type: EXPERIMENTAL
Intervention: Intervention period
Number of subjects: 4402

Group type: EXPERIMENTAL
Intervention: Completed intervention
Number of subjects: 4402

Group type: EXPERIMENTAL
Intervention: Survey assessing CFIR constructs
Number of subjects: 4402
Study: 34822128

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician's choice of treatment
Number of subjects: 0
Study: 34823566

Group type: EXPERIMENTAL
Intervention: Hearing implants
Number of subjects: 1500
Study: 34824054

Group type: EXPERIMENTAL
Intervention: Severe asthma patients (n=418)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Oral corticosteroid (OCS) use
Number of subjects: 605

Group type: COMPARATOR
Intervention: Healthy participants and mild-to-moderate asthma patients
Number of subjects: 605
Study: 34824109

Group type: EXPERIMENTAL
Intervention: Clinical pharmacists integrated into the ED team providing pharmaceutical care services such as medication reconciliation, review and/or counselling.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical pharmacists integrated into the ED team.
Number of subjects: 0
Study: 34824124

Group type: EXPERIMENTAL
Intervention: Single dose of 3 g of fosfomycin
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: 2 days of 3 g of fosfomycin o.d.
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: 3 days of pivmecillinam 400 mg three times per day (t.i.d)
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: 5 days of nitrofurantoin 100 mg t.i.d.
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1120
Study: 34824133

Group type: EXPERIMENTAL
Intervention: Perfusion-guided endovascular super-selective intra-arterial infusion of mesenchymal stem cells loaded with Delta-24 (MSC-D24)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Perfusion-guided endovascular super-selective intra-arterial infusion of MSC-D24
Number of subjects: 1
Study: 34824139

Group type: EXPERIMENTAL
Intervention: Sub-score LSM analyses
Number of subjects: 180

Group type: COMPARATOR
Intervention: Total NIHSS score
Number of subjects: 180
Study: 34824596

Group type: EXPERIMENTAL
Intervention: Janssen Ad26.COV2.S vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 34825149

Group type: EXPERIMENTAL
Intervention: Improved WASH
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Plasma intestinal fatty-acid binding protein
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Stool myeloperoxidase
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: EED biomarkers
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Household-level WASH interventions
Number of subjects: 303
Study: 34825279

Group type: EXPERIMENTAL
Intervention: Shared decision making practices in hospice interdisciplinary team meetings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attitudes of hospice staff toward shared decision making measured by the revised Leeds Attitude to Concordance scale (LatConII)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed methods analysis of hospice staff perceptions
Number of subjects: 0
Study: 34825282

Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy (NST) for 12 weeks, combinatorial based on BRAF status.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Baseline estimates prior to NST.
Number of subjects: 25
Study: 34825942

Group type: EXPERIMENTAL
Intervention: Elotuzumab plus pomalidomide/dexamethasone (E-Pd)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Elotuzumab plus lenalidomide/dexamethasone (Ld)
Number of subjects: 440
Study: 34825972

Group type: EXPERIMENTAL
Intervention: IgA on day 1
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: IgG on day 1
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: Lower levels of IgG on day 1
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: IgM on day 1
Number of subjects: 956
Study: 34825996

Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Physicians
Number of subjects: 510

Group type: COMPARATOR
Intervention: Patients with withholding/withdrawal decision
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Caregivers (nurses and physicians)
Number of subjects: 510
Study: 34826060

Group type: EXPERIMENTAL
Intervention: Regenerative Endodontic Procedures (REPs) via blood clots
Number of subjects: 10
Study: 34826114

Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (MAS) 6.25 mg once daily for 28 days
Number of subjects: 24
Study: 34826122

Group type: EXPERIMENTAL
Intervention: FLECTOR (diclofenac epolamine topical system)
Number of subjects: 104
Study: 34826124

Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 34826192

Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 156
Study: 34826353

Group type: EXPERIMENTAL
Intervention: Pegvaliase treatment with significant Phe reduction
Number of subjects: 156
Study: 34826409

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34826412

Group type: EXPERIMENTAL
Intervention: Pola-G-Len (polatuzumab vedotin 1.4 mg/kg + lenalidomide 20 mg + obinutuzumab 1000 mg)
Number of subjects: 56
Study: 34826411

Group type: EXPERIMENTAL
Intervention: BOVen regimen (zanubrutinib, obinutuzumab, and venetoclax)
Number of subjects: 39
Study: 34827232

Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 1850

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1850
Study: 34828655

Group type: EXPERIMENTAL
Intervention: 30% oxygen
Number of subjects: 34

Group type: COMPARATOR
Intervention: 60% oxygen
Number of subjects: 34
Study: 34828724

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (Rhythmic Reading Training - RRT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: In-presence rehabilitation (Rhythmic Reading Training - RRT)
Number of subjects: 30
Study: 34829796

Group type: EXPERIMENTAL
Intervention: PARP Inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 34829967

Group type: EXPERIMENTAL
Intervention: Oral bacteriotherapy (Vivomixx® in EU, Visbiome® in USA) for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 34830829

Group type: EXPERIMENTAL
Intervention: Cognitive tests (Auditory Verbal Learning Test, Letter Fluency Test, Category Fluency Test, Trail Making Test) in TC survivors
Number of subjects: 184

Group type: COMPARATOR
Intervention: Cognitive tests in healthy controls
Number of subjects: 184
Study: 34830984

Group type: EXPERIMENTAL
Intervention: Olaparib and Abiraterone
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo and Abiraterone
Number of subjects: 142
Study: 34831051

Group type: EXPERIMENTAL
Intervention: Lp(a) levels <30 mg/dL
Number of subjects: 192

Group type: COMPARATOR
Intervention: Lp(a) levels ≥30 mg/dL
Number of subjects: 192
Study: 34831060

Group type: EXPERIMENTAL
Intervention: Early gestational placental-derived mesenchymal stem/stromal cells (PMSCs)
Number of subjects: 0
Study: 34831332

Group type: EXPERIMENTAL
Intervention: Mild prolonged hypoglycemia (blood glucose maintained at 2.8 mmol/L for 1 hour)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Severe hypoglycemia
Number of subjects: 17
Study: 34831493

Group type: EXPERIMENTAL
Intervention: Online questionnaire measuring perceived stress, depression, anxiety, and resilience completed by mothers two months postpartum during the COVID-19 pandemic.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Online questionnaire measuring perceived stress, depression, anxiety, and resilience completed by mothers two months postpartum before the COVID-19 pandemic.
Number of subjects: 0
Study: 34831933

Group type: EXPERIMENTAL
Intervention: Partial centre-based with non-parents (PCN)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Full-time centre-based childcare (FC)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Partial centre-based with parental care (PCP)
Number of subjects: 540
Study: 34832978

Group type: EXPERIMENTAL
Intervention: MLR-1023
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MLR-1023 + Menthol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menthol
Number of subjects: 0
Study: 34834511

Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Fixed-Dose Combination (SFC) via Elpenhaler for 12 months
Number of subjects: 1016
Study: 34835197

Group type: EXPERIMENTAL
Intervention: ERUCoV-VAC (whole-virion inactivated SARS-CoV-2 vaccine candidate)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ERUCoV-VAC
Number of subjects: 3
Study: 34836422

Group type: EXPERIMENTAL
Intervention: Higher adherence to the DASH diet/Mediterranean diet
Number of subjects: 6209
Study: 34836504

Group type: EXPERIMENTAL
Intervention: Pandemic COVID
Number of subjects: 1649

Group type: COMPARATOR
Intervention: PreCOVID
Number of subjects: 1649
Study: 34836755

Group type: EXPERIMENTAL
Intervention: Microdialysis catheters placed at the pancreaticojejunostomy and hepaticojejunostomy
Number of subjects: 35
Study: 34836902

Group type: EXPERIMENTAL
Intervention: A Better everyday LifE (ABLE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual occupational therapy
Number of subjects: 80
Study: 34836903

Group type: EXPERIMENTAL
Intervention: Psychosocial impact assessment through a 74-question questionnaire
Number of subjects: 56656

Group type: EXPERIMENTAL
Intervention: Psychological impact measures including depression, anxiety, stress, and post-traumatic stress disorder scores
Number of subjects: 56656
Study: 34836904

Group type: EXPERIMENTAL
Intervention: Structured exercise and PA intervention with support from an exercise specialist and additional support from a smartwatch and phone app
Number of subjects: 120

Group type: COMPARATOR
Intervention: Active control (structured exercise and PA intervention supported by an exercise specialist)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Qualitative process evaluation and piloting of potential clinical outcome measures for a future RCT
Number of subjects: 120
Study: 34836907

Group type: EXPERIMENTAL
Intervention: Brief Contact Interventions (BCIs) monthly
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Brief Contact Interventions (BCIs) weekly
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Brief Contact Interventions (BCIs) biweekly
Number of subjects: 624

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 624
Study: 34836908

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) and high-intensity statins (atorvastatin or rosuvastatin) within 24 hours of stroke onset, followed by aspirin or clopidogrel alone from day 22.
Number of subjects: 138

Group type: COMPARATOR
Intervention: Single antiplatelet therapy without high-intensity statin treatment (historical control).
Number of subjects: 138
Study: 34837141

Group type: EXPERIMENTAL
Intervention: Surgical mask during maximal exercise test
Number of subjects: 26

Group type: COMPARATOR
Intervention: No mask during maximal exercise test
Number of subjects: 26
Study: 34837160

Group type: EXPERIMENTAL
Intervention: Fresh embryo transfer
Number of subjects: 4613

Group type: COMPARATOR
Intervention: Frozen embryo transfer
Number of subjects: 4613
Study: 34837382

Group type: EXPERIMENTAL
Intervention: Roselle extract capsules (total dose of 5600 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 60
Study: 34837522

Group type: EXPERIMENTAL
Intervention: PLANT (30% animal-source protein/70% plant-source protein)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 50/50 (50% animal-source protein/50% plant-source protein)
Number of subjects: 136

Group type: COMPARATOR
Intervention: 50/50 and PLANT
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: PLANT
Number of subjects: 136

Group type: COMPARATOR
Intervention: ANIMAL (70% animal-source protein/30% plant-source protein)
Number of subjects: 136
Study: 34837553

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) therapy set at 40 L/min and titrated based on improvement in ROX index and patient tolerance.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: HFNC flow set at 45 L/min at enrollment.
Number of subjects: 49
Study: 34837882

Group type: EXPERIMENTAL
Intervention: Bipolar depression
Number of subjects: 240

Group type: COMPARATOR
Intervention: Unipolar depression
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study: 34837994

Group type: EXPERIMENTAL
Intervention: Living at home
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Living at a nursing home
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Time after death
Number of subjects: 15
Study: 34838101

Group type: EXPERIMENTAL
Intervention: Life Care Specialist (LCS) intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard-of-care control
Number of subjects: 200
Study: 34838109

Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA) protocol using clonidine, magnesium sulfate, ketamine, and lidocaine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard anesthesia protocol based on opioid use
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA) protocol
Number of subjects: 140
Study: 34838114

Group type: EXPERIMENTAL
Intervention: S-ketamine (0.2 mg/kg)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: S-ketamine (0.4 mg/kg)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control treatment without S-ketamine
Number of subjects: 210
Study: 34838125

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT) and work-focused interventions
Number of subjects: 240

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 240
Study: 34838325

Group type: EXPERIMENTAL
Intervention: Guardant360 CDx plasma testing for KRAS p.G12C mutations
Number of subjects: 126

Group type: COMPARATOR
Intervention: Therascreen® KRAS RGQ PCR kit tissue testing
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Overall response rate (ORR)
Number of subjects: 126
Study: 34838464

Group type: EXPERIMENTAL
Intervention: PPM (Prosthesis-Patient Mismatch)
Number of subjects: 1101

Group type: COMPARATOR
Intervention: PPM
Number of subjects: 1101